PE Guidelines logo
Pharmacoeconomic Guidelines Around The World

Country/Region: France

PE Guidelines
French Guidelines for the Economic Evaluation of Health Care Technologies (September 2004) (French Version 2003)
PDF in English; PDF in French

PE Guidelines Source:

Additional Information:

Last Webpage Update:

PE Guidelines Key Features:

Key Features:  
Title and year of the documentFrench Guidelines for the Economic Evaluation of Health Care Technologies (September 2004) (French Version 2003) 
Affiliation of authorsThe members of the Collège des Économistes de la Santé (the French Health Economists Association) 
Purpose of the documentProvide methodological and reporting guidelines for PE evaluations. 
Standard reporting format includedYes 
DisclosureYes 
Target audience of funding/ author's interestsDecision makers, researchers, pharmaceutical companies 
PerspectiveEconomic evaluation studies of health care programmes must adopt the widest possible perspective in order to include all the relevant outcomes of each programme studied. The choice of the range of observation must be justified. 
IndicationApproved indication 
Target populationThe target population of the evaluation must be clearly described. 
Subgroup analysisYes 
Choice of comparatorThe therapeutic strategies to be used as comparators will be chosen among those most frequently used (including non-treatment) or newer strategies which may legitimately be deemed likely to become reference strategies in the very near future. 
Time horizonLong enough that all outcomes, both positive and negative, of the treatments used and evaluated be included in the study. 
Assumptions requiredYes 
Preferred analytical techniqueAny one of CMA, CEA, CUA, CBA, and CCA. The choice must be justified. 
Costs to be includedDepends on the aim of the study. All costs that are relevant must be distinguished and presented in detail. Report indirect costs separately. 
Source of costsThe identification, measurement and valuation of costs should be consistent with the perspective of the Programme de Médicalisation des Systèmes d'Information (PMSI) [the medical information system which is the French DRG program]. 
ModelingYes, requires details. 
Systematic review of evidencesYes 
Preference for effectiveness over efficacyEffectiveness is to be preferred to efficacy. If, however, efficacy is the sole indicator available, every effort should be made to convert this into effectiveness by means of appropriate adjustments. 
Preferred outcome measureFinal outcomes preferred. 
Preferred method to derive utilityThe methods most commonly used to identify preferences are the SG, TTO, and VAS methods. These methods allow for the expression of individual preferences within a strict framework. 
Equity issues statedYes 
Discounting costsFor the purposes of international comparisons the rates used should be 0%, 3% and 5%. 
Discounting outcomesFor the purposes of international comparisons the rates used should be 0%, 3% and 5%. 
Sensitivity analysis-parameters and rangeMaintain uncertain variables. 
Sensitivity analysis-methodsA distinction is made between univariate and multivariate analysis, and also between first order and second order analysis. 
Presenting resultsThe results of an economic evaluation study should be presented in such a way as to allow peer examination and review. 
Incremental analysisYes 
Total costs vs effectiveness (cost/effectiveness ratio)Cost-effectiveness (or cost-utility ratios) must be expressed in incremental form so that they may be used as a criterion to assist in decision-making. 
Portability of results (Generalizability)When the economic evaluation study relies on international data or national data for a country other than France, the authors should demonstrate that these data may be transferred with sufficient plausibility to the French context. 
Financial impact analysisYes 
Mandatory or recommended or voluntaryRecommended 

Country Selection Page | PE Guidelines Index Page